The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A

Peptides

Volumn 17, Issue 4, 1996, Pages 601-607

  Migaud, Martine ^a   Durieux, Christiane ^a   Viereck, Jason ^a   Soroca Lucas, Evelyne ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Aminopeptidase A; CCK 8; Cholecystokinin; Cortex; Degradation; EC 33 (3 amino 4 thio butyl sulfonate); Hippocampus; In vivo binding assay; K+ evoked release; Mouse; Peptidase inhibitors; Rat

Indexed keywords

AMINOPEPTIDASE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; EC 33; ENZYME INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN SLICE; CONTROLLED STUDY; HIPPOCAMPUS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALIA; FELIS CATUS;

EID: 0029978990     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/0196-9781(96)00036-8     Document Type: Article

References (47)

1. 1. Benoliel, J. J.; Mauborgne, A.; Bourgoin, S.; Legrand, J. C.; Hamon, M.; Cesselin, F. Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra. J. Neurochem. 58:916-922; 1992.
2. B receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro. Brain Res. 590:255-262; 1992.
3. 3. Bradwejn, J.; Koszycki, D.; Couétoux du Tertre, A.; et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry 51:486-493; 1994.
4. 4. Bray, S.; Bustos, G. A.; Lee, P. H. K.; Hong, J. S.; Aitken, P. G.; Nadler, J. V. Kainic acid inhibits cholecystokinin release from rat hippocampal slices. Neurosci. Lett. 100:313-318; 1989.
5. 5. Butcher, S. P.; Varro, A.; Kelly, J. S.; Dockray, G. J. In vivo studies on the enhancement of cholecystokinin release in the rat striatum by dopamine depletion. Brain Res. 505:119-122; 1989.
6. 6. Chauvel, E. N.; Llorens-Cortès, C.; Coric, P.; Wilk, S.; Roques, B. P.; Fournié-Zaluski, M. C. Differential inhibition of aminopeptidase A and aminopeptidase N by new β-amino thiols. J. Med. Chem. 37:2950-2957; 1994.
7. 7. Chauvel, E. N.; Coric, P.; Llorens-Cortès, C.; Wilk, S.; Roques, B. P.; Fournié-Zaluski, M. C. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors. J. Med. Chem. 37:1339-1346; 1994.
8. 3H]pBC 254. J. Label. Compd. Radiopharm. 31:459-468; 1992.
9. 9. Crawley, J. N. Comparative distribution of cholecystokinin and other neuropeptides. Ann. NY Acad. Sci. 448:1-8; 1985.
10. B antagonists in mice: Antagonism by naltrindole. Br. J. Pharmacol. 111:956-960; 1994.
11. 11. Deschodt-Lanckman, M., Bui. N. D.; Noyer, M.; Christophe, J. Degradation of cholecystokinin-like peptides by a crude rat brain synaptosomal fraction: A study by high pressure liquid chromatography. Regul. Pept. 2:15-30; 1981.
12. 12. Dubreuil, P.; Fulcrand, P.; Rodriguez, M.; Fulcrand, H.; Laur, J.; Martinez, J. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the C-amidated C-terminal dipeptide. Biochem. J. 262:125-130; 1989.
13. 13. Durieux, C., Charpentier, B.; Pélaprat, D.; Roques, B. P. Investigation on the metabolism of CCK-8 analogues by rat brain slices. Neuropeptides 7:1-9; 1986.
14. 14. Durieux, C.; Charpentier, B.; Fellion, E.; Gacel, G.; Pélaprat, D.; Roques, B. P. Multiple cleavage sites of cholecystokinin heptapeptide by enkephalinase. Peptides 6:495-501; 1985.
15. 3H]pBC 264. Eur. J. Pharmacol. 209:185-193; 1991.
16. 3H]SNF 8702. Mol. Pharmacol. 41:1089-1095; 1992.
17. 17. Faris, P. L.; McLaughlin, C. L.; Baile, C. A.; Olney, J. W.; Komisaruk, B. R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 226:1215-1217; 1984.
18. 18. Fournié-Zaluski, M. C.; Coric, P.; Turcaud, S.; et al. Potent and systemically active aminopeptidase N inhibitors designed from active site investigation. J. Med. Chem. 35:1259-1266; 1992.
19. 19. Gomez-Monterrey, I.; Beaumont, A.; Nemecek, P.; Roques, B. P.; Fournié-Zaluski, M. C. New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: Synthesis and enzyme active-site recognition. J. Med. Chem. 37:1865-1873; 1994.
20. 20. Griesbacher, T.; Leighton, G. E.; Hill, R. G.; Hughes, J. Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases. Br. J. Pharmacol. 96:236-242; 1989.
21. 21. Healy, D. P.; Wilk, S. Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res. 606:295-303; 1993.
22. 22. Hendry, S. H. C.; Jones, E. G.; Beinfeld, M. C. Cholecystokinin-immunoreactive neurons in rat and monkey cerebral cortex make symmetric synapses and have intimate associations with blood vessels. Proc. Natl. Acad. Sci. USA 80:2400-2404; 1983.
23. 23. Itoh, S.; Lal, H. Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 21:257-276; 1990.
24. 24. Jurna, I.; Zetler, G. Antinociceptive effect of centrally administered caerulcin and cholecystokinin octapeptide (CCK-8). Eur. J. Pharmacol. 73:323-331; 1981.
25. 25. Li, Z. W.; Bijl, W. A. A. J.; Van Nispen, J. W.; Brendel, K.; Davis, T. P. Neuropeptide processing in regional brain slices: Effect of conformation and sequence. J. Pharmacol. Exp. Ther. 253:851-857; 1990.
26. 26. Lynch, G.; Schubert, P. The use of in vitro brain slices for multi-disciplinary studies of synaptic function. Annu. Rev. Neurosci. 3:1-22; 1980.
27. B antagonist strongly enhances antinociceptive responses. Neuroreport 4:947-950; 1993.
28. 28. Matsas, R.; Turner, A. J.; Kenny, A. J. Endopeptidase-24.11 and aminopeptidase activity in brain synaptic membranes are jointly responsible for the hydrolysis of cholecystokinin octapeptide (CCK-8). FEBS Lett. 175:124-128; 1984.
29. 29. McDermott, J. R.; Dodd, P. R.; Edwardson, J. A.; Hardy, J. A.; Smith, A. I. Pathway of inactivation of cholecystokinin octapeptide (CCK-8) by synaptosomal fractions. Neurochem. Int. 5:641-647; 1983.
30. 30. Migaud, M.; Roques, B. P.; Durieux, C. Evidence for a high-affinity uptake system for cholecystokinin octapeptide (CCK-8) in rat cortical synaptosomes. Eur. J. Neurosci. 7:1074-1079; 1995.
31. 1251]Bolton-Hunter CCK-8. Functional significance of subregional distribution. Neurochem. Int. 10:495-508; 1987.
32. 32. Roques, B. P.; Noble, F.; Daugé, V.; Fournié-Zaluski, M. C.; Beaumont, A. Neutral endopeptidase 24.11 : structure, inhibition and experimental and clinical pharmacology. Pharmacol. Rev. 45:87-146; 1993.
33. 33. Roques, B. P.; Fournié-Zaluski, M. C.; Soroca, E.; et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288:286-288; 1980.
34. 34. Rose, C.; Camus, A.; Schwartz, J. C. A serine peptidase responsible for the inactivation of endogenous cholecystokinin in brain. Proc. Natl. Acad. Sci. USA 85:8326-8330; 1988.
35. 35. Rose, C.; Vargas, F.; Silhouette, B.; Devaux, B.; Schwartz, J. C. Characterization of a serine peptidase responsible for the inactivation of endogenous cholecystokinin in human brain. Neuropeptides 28:157-160; 1995.
36. 36. Singh, L.; Lewis, A. S.; Field, M. J.; Hughes, J.; Woodruff, G. N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA 88:1130-1133; 1991.
37. 37. Smith, G. P.; Gibbs, J. The satiety effect of cholecystokinin, recent progress and current problems. Ann. NY Acad. Sci. 448:417-423; 1985.
38. 38. Song, L; Wilk, E.; Wilk, S.; Healy, D. P. Localization of immunoreactive glutamyl aminopeptidase in rat brain. I. Association with cerebral microvessels. Brain Res. 606:286-294; 1993.
39. 39. Tobe, H.; Kojima, F.; Aoyagi, T.; Umezawa, H. Purification by affinity chromatography using amastatin and properties of aminopeptidase A from pig kidney. Biochim. Biophys. Acta 613:459-468; 1980.
40. 40. Turner, A. J.; Matsas, R.; Kenny, A. J. Are there neuropeptide-specific peptidases? Biochem. Pharmacol. 34:1347-1356; 1985.
41. 41. Vanderhaeghen, J. J.; Lotstra, F.; de Mey, J.; Gilles, C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. Proc. Natl. Acad. Sci. USA 77:1190-1194; 1980.
42. 42. Waksman, G.; Bouboutou, R.; Devin, J.; et al. In vivo and in vitro effects of kelatorphan on enkephalin metabolism in rodent brain. Eur. J. Pharmacol. 117:233-243; 1985.
43. 43. Wank, S. A.; Pisegna, J. R.; de Weerth, A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc. Natl. Acad. Sci. USA 89:8691-8695; 1992.
44. 44. Wilk, S. ; Healy, D. P. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Adv. Neuroimmunol. 3:195-207; 1993.
45. 45. Wilson, C.; Gibson, A. M.; McDermott, J. R. Purification and characterization of tripeptidylpeptidase-II from postmorten human brain; Neurochem. Res. 18:743-749; 1993.
46. 46. Wu, Q.; Lahti, J. M.; Air, G. M.; Burrows, P. D.; Cooper, M. D. Molecular cloning of the murine BP-1/6C3 antigen: A member of the zinc-dependent metallopeptidase family. Proc. Natl. Acad. Sci. USA 87:993-997; 1990.
47. 47. Zuzel, K. A.; Rose, C.; Schwartz, J. C. Assessment of the role of "enkephalinase" in cholecystokinin inactivation. Neuroscience 15:149-158; 1985.